Amgen: Prostatic Neoplasms trials

The registry lists 22 Prostatic Neoplasms studies with Amgen as lead sponsor. 5 are open to participants now and 10 have results posted.

Phase 1 9Phase 2 3Phase 3 10No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate CancerRecruitingNCT07493512Phase 1
• A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerRecruitingNCT07213674Phase 3
• Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate CancerRecruitingNCT07140900Phase 1
• Evaluation of Neoadjuvant Xaluritamig in Localized Prostate CancerRecruitingNCT06613100Phase 1
• Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate CancerRecruitingNCT04221542Phase 1
• A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate CarcinomaTerminatedNCT04740034Phase 1Results posted
• Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate CancerCompletedNCT01824342Phase 3Results posted
• Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced AnaemiaCompletedNCT01444456Results posted
• Open-Label Access Protocol of Denosumab for Subjects With Advanced CancerCompletedNCT01419717Phase 3Results posted
• Open Label Extension to SRE Studies in United Kingdom and Czech Republic OnlyCompletedNCT00950911Phase 3Results posted
• Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone LossCompletedNCT00925600Phase 3Results posted
• Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate CancerCompletedNCT00838201Phase 3Results posted
• Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate CancerCompletedNCT00321620Phase 3Results posted
• Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate CancerCompletedNCT00286091Phase 3Results posted
• AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate CancerCompletedNCT00089674Phase 3Results posted
• Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)Active, not recruitingNCT06691984Phase 3
• Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate CancerActive, not recruitingNCT06555796Phase 1
• Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPCTerminatedNCT03792841Phase 1
• AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate CancerCompletedNCT00770848Phase 1/2
• AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin LymphomaCompletedNCT00562380Phase 1
• ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the BodyCompletedNCT00061126Phase 2
• Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone TherapyStatus unknownNCT00005960Phase 2